留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

临床药师参与重症医学科药物治疗实践的体会

曹伟 方洁

曹伟, 方洁. 临床药师参与重症医学科药物治疗实践的体会[J]. 药学实践与服务, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021
引用本文: 曹伟, 方洁. 临床药师参与重症医学科药物治疗实践的体会[J]. 药学实践与服务, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021
CAO Wei, FANG Jie. The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021
Citation: CAO Wei, FANG Jie. The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021

临床药师参与重症医学科药物治疗实践的体会

doi: 10.3969/j.issn.1006-0111.2017.04.021

The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine

  • 摘要: 目的 探讨重症医学科临床药师开展工作所需技能。 方法 结合工作中典型案例进行分析和阐述。 结果 重症医学科临床药师深入临床培养临床思维、与医护人员积极沟通,并结合药学专业知识及循证医学证据,协助临床解决实际用药问题。 结论 重症医学科临床药师开展工作时需兼具临床与药学两种思维,并注重用药细节,充分运用循证医学证据。
  • [1] 刘 青,王泰龄. 慢加急性肝衰竭(ACLF)共识纪要:亚太肝病学会推荐(APASL)[J]. 临床肝胆病杂志[J],2010,26(1):13-18.
    [2] 刘海华,王锦权. 脓毒症致急性肾损伤发病机制和临床防治的研究进展[J]. 感染、炎症、修复,2009,10(2):126-128.
    [3] Jay P Sanford. 热病——桑福德抗微生物治疗指南[M]. 范洪伟等译.44版. 北京:中国协和医科大学出版社,2015:211-213.
    [4] 陈灏珠,林果为. 实用内科学[M].13版. 北京:人民卫生出版社,2012:2173-2174.
    [5] Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J]. Lancet Infect Dis, 2014,14(6):498-509.
    [6] Ulldemolins M, Soy D, Llaurado-Serra M, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy:influence of residual diuresis on dose requirements[J]. Antimicrob Agents Chemother, 2015,59(9):5520-5528.
    [7] 国家药典委员会. 中华人民共和国药典2015年版四部[S]. 北京:中国医药科技出版社,2015:118.
    [8] Rowland M, Tozer TN. 临床药代动力学与药效动力学 [M]. 陈东生等译.4版. 北京:人民卫生出版社,2012:112.
    [9] Williams MF, Dukes GE, Heizer W, et al. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine[J]. Pharm Res,1992,9(9):1190-1194.
    [10] 杨文琳,王美霞. 血液净化救治急性药物或毒物中毒[J]. 中国危重病急救医学,2005,17 (11):704-704.
    [11] 尧国胜,李 军,黄 高,等. 急性重症中毒血液净化治疗的进展[J]. 右江民族医学院学报,2015,37(1):131-134.
    [12] Rhodes NJ, MacVane SH, Kuti JL, et al. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes[J]. Clin Infect Dis, 2014,59(6):905-907.
    [13] Luke DR, Wood ND, Tomaszewski KE, et al. Pharmacokinetics of sulfobutylether-b-cyclodextrin (SBECD) in subjects on hemodialysis[J]. Nephrol Dial Transplant,2012,27(3):1207-1212.
    [14] Hafner V, Czock D, BurhenneJ, et al.Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration[J]. Antimicrob Agents Chemother, 2010,54(6):2596-2602.
    [15] Kiser TH, Fish DN, Aquilante CL, et al.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy[J]. Crit Care, 2015,18(3):32-40.
    [16] Turner RB, Martello JL, Malhotra A. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole:A systematic review[J]. Int J Antimicrob Agents, 2015,46(4):362-366.
    [17] Atiq F, van den Bemt PM, Leebeek FW, et al. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency[J]. Eur J Clin Pharmacol, 2015,71(8):921-929.
    [18] Park D, Southern W, Calvo M, et al. Treatment with Dalteparin is associated with a lower risk of bleeding compared to treatment with unfractionated heparin in patients with renal insufficiency[J]. J Gen Lntern Med, 2016,31(2):182-187.
  • [1] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [2] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
  • 加载中
计量
  • 文章访问数:  2602
  • HTML全文浏览量:  254
  • PDF下载量:  654
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-11-24
  • 修回日期:  2017-03-06

临床药师参与重症医学科药物治疗实践的体会

doi: 10.3969/j.issn.1006-0111.2017.04.021

摘要: 目的 探讨重症医学科临床药师开展工作所需技能。 方法 结合工作中典型案例进行分析和阐述。 结果 重症医学科临床药师深入临床培养临床思维、与医护人员积极沟通,并结合药学专业知识及循证医学证据,协助临床解决实际用药问题。 结论 重症医学科临床药师开展工作时需兼具临床与药学两种思维,并注重用药细节,充分运用循证医学证据。

English Abstract

曹伟, 方洁. 临床药师参与重症医学科药物治疗实践的体会[J]. 药学实践与服务, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021
引用本文: 曹伟, 方洁. 临床药师参与重症医学科药物治疗实践的体会[J]. 药学实践与服务, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021
CAO Wei, FANG Jie. The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021
Citation: CAO Wei, FANG Jie. The pharmacotherapy practices of clinical pharmacist in Department of Critical Care Medicine[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 371-374. doi: 10.3969/j.issn.1006-0111.2017.04.021
参考文献 (18)

目录

    /

    返回文章
    返回